Return-path: <>
Envelope-to: lbaez@edenetsa.com
Delivery-date: Tue, 04 Nov 2014 01:58:33 -0400
Received: from [98.155.220.86] (port=65321 helo=98.155.220.86)
	by host8.dnns.net with smtp (Exim 4.82)
	id 1XlX8S-0004N7-Vh
	for lbaez@edenetsa.com; Tue, 04 Nov 2014 01:58:33 -0400
Received: from unknown (HELO localhost) (joanbru@maine207.org@47.49.128.50)
	by 98.155.220.86 with ESMTPA; Mon, 3 Nov 2014 19:58:15 -1000
X-Originating-IP: 47.49.128.50
From: joanbru@maine207.org
To: lbaez@edenetsa.com
Subject: Get Ready For our New Alert

"Oncolytics Biotech" Biotechnology Company is focused on the development of 
oncolytic viruses for their further use in the treatment of various forms of 
cancer. The top company's drug - "REOLYSIN" - is currently in the final stage 
of clinical testings against cancer of head and neck. The medicine's action 
is based on the reovirus (Respiratory Enteric Orphan virus) ability to 
identify and "infect" the cells with the mutated RAS gene. After mutation the 
gene transforms an ordinary cell into a cancer one. "REOLYSIN", made by the 
Canadian company "Oncolytics Biotech Inc", not only finds the cancer cells 
with the mutated gene, but is also cytocidal. Given that 2/3 of tumors have 
cells with the mutated RAS gene, there is a hope that complex and even 
propagating tumors might be treated without radiation and chemotherapy.

According to recent data, the application of the reovirus medicine in 
combination with chemotherapeutic treatment enlarges the ratio of favorable 
outcome for the treatment of the head and neck tumors up to 74%.

"Oncolytics Biotech Inc (ONCY)" Company's stock are available on NASDAQ since 
2001, Market Cap 72.36M, rated by Zacks "Strong Buy". As of the end of 
trading on 03/11/2014, the share price was $0.88, which is a good entry point 
for investing in new emerging technologies.

Let us recall that "Oncolytics Biotech Inc" Company was established in 
Calgary in 1998 in response to discoveries made on the oncolytic potential of 
reovirus at the University of Calgary in the 1990s. From 1999 to 2000 the 
enterprise transitioned from private to public ownership. 

The company was granted its first Canadian patent in August 2000, and 
currently holds more than 200 patents worldwide, including 38 U.S. and 11 
Canadian patents.